Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
Thibaut GeléAntoine ChéretAlicia Castro GordonLionelle NkamValérie FurlanCoralie PallierPierre-Hadrien BeckerPilartxo CatalanCécile GoujardAnne-Marie TaburetJacques GasnaultHélène GougetAurélie Barrail-TranPublished in: The Journal of antimicrobial chemotherapy (2021)
We observed low CSF exposure to bictegravir, emtricitabine and tenofovir. These results suggest that BIC/FTC/TAF should be used with caution as first-line treatment for people living with HIV with HCI under 51 years of age.